A Phase I/II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of MT-2766 in Japanese Adults (COVID-19)
Latest Information Update: 10 Oct 2024
At a glance
- Drugs MT 2766 (Primary) ; AS03A
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Medicago
- 07 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 27 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.
- 27 Jan 2022 Status changed from recruiting to active, no longer recruiting.